GlassScriptPhysician profile
Amrit S Bhangoo
NPI 1982882254
$139,635.24
in general payments reported to CMS, 2019-2025
41 companies · $84K in 2025
The $84K reported for 2025 was more than what 99% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,600 · 2020: $7,733 · 2021: $3,669 · 2022: $5,751 · 2023: $13K · 2024: $21K · 2025: $84K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $73K · Consulting Fee: $30K · Travel and Lodging: $8,932 · Food and Beverage: $5,004 · Education: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $73,088.26 |
| Consulting Fee | $30,408.11 |
| Travel and Lodging | $8,931.73 |
| Food and Beverage | $5,004.17 |
| Education | $449.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $47,221.35 | 2020-2025 | Voxzogo 1.2mg |
| Neurocrine Biosciences, INC. | $34,908.45 | 2024-2025 | |
| Novo Nordisk INC | $27,714.28 | 2019-2025 | Sogroya, Wegovy, Rybelsus |
| Pfizer INC. | $9,108.76 | 2019-2025 | |
| Arbor Pharmaceuticals, INC. | $4,392.34 | 2019-2021 | |
| Abbvie INC. | $3,591.33 | 2019-2025 | Lupron Depot |
| Dexcom, INC. | $3,496.76 | 2019-2024 | Dexcom G6 Transmitter |
| Rhythm Pharmaceuticals, INC. | $2,937.51 | 2021-2024 | Imcivree |
| Eton Pharmaceuticals, INC. | $2,069.62 | 2023-2025 | Alkindi, Khindivi, Increlex |
| Alexion Pharmaceuticals, INC. | $1,170.83 | 2019-2025 | Strensiq |
| Ascendis Pharma Endocrinology INC | $618.11 | 2022-2025 | Skytrofa |
| Sanofi-Aventis U.S. LLC | $500.87 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $217.65 | 2019-2020 | |
| Lilly USA, LLC | $211.77 | 2019-2023 | Baqsimi |
| Kyowa Kirin, INC. | $185.19 | 2024-2025 | Crysvita |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $173.83 | 2022 | |
| Medtronic, INC. | $152.69 | 2022-2023 | Minimed 780g, Mycarelink, Inpen Smart Insulin Delivery System |
| Travere Therapeutics, INC. | $145.65 | 2019-2022 | |
| Insulet Corporation | $122.77 | 2019-2025 | Omnipod |
| Tandem Diabetes Care, INC. | $90.56 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Becton, Dickinson and Company | $71.92 | 2019-2022 | |
| Abbott Laboratories | $53.10 | 2019-2021 | |
| Beta Bionics, INC. | $52.65 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Medtronic Minimed, INC. | $49.88 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $49.28 | 2020-2022 | |
| Ascensia Diabetes Care US INC. | $43.52 | 2019 | |
| Amarin Pharma, INC. | $42.01 | 2019 | |
| Galen US INC | $36.40 | 2019 | |
| Senseonics, Incorporated | $34.00 | 2019 | |
| Greenwich Biosciences, INC. | $30.06 | 2019 | |
| Sequel Med Tech, LLC | $26.15 | 2025 | Twiist |
| Takeda Pharmaceuticals U.S.A., INC. | $24.26 | 2025 | Alunbrig |
| Horizon Therapeutics Plc | $22.29 | 2021 | |
| Azurity Pharmaceuticals, INC. | $21.83 | 2025 | Triptodur |
| Genzyme Corporation | $18.23 | 2019 | |
| Amryt Pharma Holdings LTD | $17.46 | 2021 | |
| Sobi, INC | $11.88 | 2020 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amrit Bhangoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.